课题基金 / 基金详情

CLINICAL SCALE EXPANSION OF HUMAN DENDRITIC CELLS

CLINICAL SCALE EXPANSION OF HUMAN DENDRITIC CELLS
人类树突状细胞的临床规模扩张
批准号:
2645337
负责人:
DOUGLAS Matthew SMITH
金额:
$9.88万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-06-01 至 1998-11-30

项目摘要

项目成果

DOUGLAS Matthew SMITH的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (Adapted from the applicant's abstract): Dendritic cells (DCS) are highly specialized bone marrow-derived antigen presenting cells (APCs) which function as potent stimulating cells for T- lymphocyte-mediated immune responses. Dendritic cell-based immunotherapy is an emerging treatment strategy involving ex vivo expansion and reinfusion of antigen-pulsed DCS into human patients to vaccinate against cancer or infectious diseases. A major limitation in this approach has been the capability to generate sufficient quantities of functional DCS for effective patient therapy. The primary objective of the proposed studies is to develop and implement a unique process for ex vivo expansion, differentiation, tumor antigen-loading and harvest of DCS in a continuously perfused clinical-scale bioreactor system. The hypothesis that continuous single-pass medium exchange will enable enhanced production of functional DCS at high density in Aastrom's Cell Production System (CPS) will be tested. The Phase II program will focus on optimization and full automation of the process in compliance with GMP regulations. The automated system will be tested in clinical trials to assess the safety and efficacy of dendritic cells produced in the CPS for human carcino-embryonic antigen (CEA-specific cancer therapy. An automated clinical scale bioreactor system would enable efficient production of highly functional dendritic cells as a superior APC type for cancer immunotherapy. PROPOSED COMMERCIAL APPLICATION: A closed, automated, GMP system for dendritic cell expansion, differentiation, antigen-loading and harvest would be of great value for immunotherapy of cancer and infectious diseases. The existing methods for dendritic cell expansion involve multiple open process steps with associated costs in equipment and labor. The development of a CPS-based DC expansion process will enable widespread application of successful dendritic cell-based therapies in a reliable and cost-effective fashion.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Dendritic Cell Subset for Enhanced Cancer Vaccine
  • 批准号:
    6832676
  • 项目类别:
  • 资助金额:
    $10.96万
  • 财政年份:
    2004
  • 负责人:
    DOUGLAS Matthew SMITH
  • 依托单位:
Bioreactor for Enhanced T-cell Based Therapy of Melanoma
  • 批准号:
    6791918
  • 项目类别:
  • 资助金额:
    $12.42万
  • 财政年份:
    2004
  • 负责人:
    DOUGLAS Matthew SMITH
  • 依托单位:
Enhanced Tumor Antigen Priming of Dendritic Cell Vaccine
  • 批准号:
    6644684
  • 项目类别:
  • 资助金额:
    $10.13万
  • 财政年份:
    2003
  • 负责人:
    DOUGLAS Matthew SMITH
  • 依托单位:
EXPANSION AND GENETIC TRANSDUCTION OF EBV-SPECIFIC CTLS
  • 批准号:
    2867484
  • 项目类别:
  • 资助金额:
    $9.98万
  • 财政年份:
    1999
  • 负责人:
    DOUGLAS Matthew SMITH
  • 依托单位: